Clinical Trial Packaging Market Size - By Material Type, By Product Type, and By End Use- Global Forecast, 2025 - 2034

Clinical Trial Packaging Market Share

The global clinical trial packaging market was valued at USD 3.7 billion in 2024 and is estimated to grow at a CAGR of 10.2% to reach USD 9.9 billion by 2034, attributed to the growth in biologics and complex drug formulations coupled with the rising number of clinical trials globally.
 

The growth in biologics and drug formulations is a major growth driver in the clinical trial packaging market. For instance, according to Statista, the global drug discovery market is expected to surpass USD 71 billion by 2025. This increasing drug and biologics formulations requires unique handling and storage needs for therapies and biologics such as monoclonal antibodies, vaccines and gene therapy. These therapies and biologics are highly sensitive to sunlight, temperature, and contamination, and thus rely on specialized packaging which ensures product integrity.
 

Additionally, several drugs and biologics are produced in smaller and customized batches, which further pushes the demand for flexible, scalable, and regulated clinical trial packaging formats.
 

Clinical trial packaging manufacturers should invest in advanced, temperature-controlled, and temper-evident packaging solutions to maintain stability of sensitive solutions for biologics such as monoclonal antibodies, vaccines, and gene therapies. Flexible options for smaller, tailored batches will meet the surging need effectively.
 

Another significant growth driver in clinical trial packaging is the stringent packaging regulations for drug safety. Various regulatory bodies such as FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and WHO (World Health Organization) enforces strict packaging guidelines to ensure integrity, traceability, and security of clinical trial materials. This regulatory requirement is driving the adoption of tamper evident, clear and compliant labels, and secure packaging to prevent contamination, counterfeiting, and mishandling of drugs. Furthermore, the increasing investment from pharmaceutical companies for advanced and secure packaging technologies while complying with growing complex regulations from the government, further supports the clinical trial packaging market expansion.
 

Packaging manufacturers should prioritize compliance with global standards, ensuring traceability and product integrity. Collaborations with pharmaceutical companies for early stage packaging development can ensure compliance with regulatory requirements. Innovation in anti-counterfeiting packaging will differentiate from competitors.
 

Clinical Trial Packaging Market Trends

• The rapid adoption of the smart temperature indicators (STIs) is a major trend in the clinical trial packaging industry. STIs are gaining traction among manufacturers as a cost-effective, visual tool, which provides real time indication of temperature. Moreover, these indicators offer enhanced compliance, and wastage reduction while adding a layer of safety, which further attracts pharmaceutical companies to adopt these STIs.
   
• The adoption of RFID, NFC tags and temperature logger system in clinical trial packaging market to enhance drug security is another significant trend. Manufacturers are increasingly incorporating tamper evident seals and unique identification codes to enhance traceability and improve supply chain efficiency and transparency.
   
• Another major trend in the market is the increasing demand for outsourcing to Contract Packaging Organizations (CPOs). Various pharmaceutical companies are shifting towards specialized CPOs, which provide cost effective, scalable, and compliant packaging. This trend is driven by the growing market specialization and innovation.
   

Clinical Trial Packaging Market Analysis

Based on the material the market is categorized as plastic, glass, metal, and paper and paperboard.
 

• The plastic material segment is the largest market and was valued at USD 1.8 billion in 2024. Plastic materials offer lightweight and cost-effective packaging, which is ideal for bulk shipping, storage and decentralized clinical trials (DCTs). Also, these materials are highly customizable and flexible and are therefore gaining rapid traction amongst manufacturers to support customized kit and small batch packaging formats such as blister packs, prefilled syringes, and pouches. Furthermore, the advancements in technology are pushing the adoption of multi-layer plastic and composites for oral solid dosages and injectables to ensure drug stability, due to their superior protection from moisture, oxygen, and UV protection, which pushes the growth of plastic materials in the clinical trial packaging market.
   
• The glass material segment is projected to grow with a CAGR of 9.5% during 2025 to 2034. The growth of this segment is driven by the increasing demand for type 1 borosilicate glass, which is highly preferred for clinical trials such as biologics, vaccines, and injectables, to ensure drug efficacy due to its chemical inertness. Additionally, the increasing demand for cold chain applications, which require glass vials and ampoules to ensure stability under cold conditions, along with the rise in precision medicine and sterile injectable trials, which require high-purity glass packaging, are further supporting the segment growth.

The clinical trial packaging market based on the end user is categorized as research laboratories, clinical research organizations, and drug manufacturing facilities.
 

• The research laboratories segment is the largest market and was valued at USD 1.6 billion in 2024. The research laboratories heavily rely on phase 1 trials and preclinical studies, which require small batch, flexible, and compliant packaging to handle several drug formulations. Also, the rise of targeted therapy, gene editing, and biologics are further propelling the demand for sterile and temperature-sensitive packaging such as glass vials and cryogenic containers. Moreover, Research laboratories require secure, tamper-evident, and trackable packaging for sample collection, storage and transportation, especially for biospecimens and drug efficacy monitoring and the increasing regulatory requirements on laboratory trials to meet GMP/GLP standards to ensure traceability and audit readiness, further solidify the position of this segment in clinical trial packaging market.
   
• The clinical research organizations segment is the fastest growing segment and is projected to grow with a CAGR of 12% during the forecast period. The growth in this segment is driven by the rapid expansion of global trial and multi-site management, which export ready and scalable packaging. Also, pharmaceutical companies are increasingly leaning on CROS for outsourced trial operations, boosts the demand for full service clinical trial packaging for custom kitting, labelling, and logistics.
   

The clinical trial packaging market based on the product is categorized as syringes, vials & ampoules, blisters, tubes, bottles, bags & pouches, kits or packs, and others.
 

• The vials and ampoules segment is the largest market and was valued at USD 864.4 million in 2024. The rise of biologics, vaccines, and injectable therapy coupled with the increasing demand for pre-sterilized and ready to use vials are the major growth drivers for this segment. These glass vials & ampoules are dominated the market due to their superior sterility, chemical inertness, and dosage accuracy. Additionally, the increasing demand for cold chain compatible packaging are further pushing the demand for type 1 borosilicate glass vials, which are ideal for temperature sensitive drugs.
   
• The kits and packs segment is the fastest growing segment and is projected to grow with a CAGR of 12.5% during 2025 to 2034. The growth in this segment is driven by the shift towards home based trials and remote patient participation coupled with the increasing demand for cost effective and light weight packaging, which makes kits & packs ideal for bulk shipping and international transportation. Moreover, these kits enable bundling of multiple trial components such as syringes, vials, and instruction manual to cater personalized therapy and small batch trials, further supports the growth of kits and packs segment.

The North America region accounted for over 41.5% revenue share of the global clinical trial packaging market in 2024. The surge in clinical trials for biologics, personalized medicine, and rare disease therapy are the major growth drivers in North America. Additionally, the increasing governmental investment towards decentralized clinical trials (DCTs) and cold chain infrastructure is driving the adoption of specialized packaging solutions for temperature-sensitive and patient centric products, which supports market expansion in the region.
 

• The U.S. dominated the clinical trial packaging market, accounting for USD 1.3 billion in the year 2024. The country has a developed pharmaceutical industry along with the increasing production and export of biologics and vaccines especially in the oncology, immunotherapy, and biotechnology sectors are the major growth drivers in the region. For instance, according to Statista, the U.S. was the largest pharmaceutical industry in the year 2023, generating more than USD 670 billion in revenue. In addition, the rapid expansion of contract packaging organizations (CPOs) and contract research organizations (CROs) coupled with the increasing clinical trials further support the market growth.
   
• The Canada clinical trial packaging market is projected to grow at a CAGR of over 7.5% till 2034. The rapid expansion of robust clinical infrastructure coupled with the increasing initiatives from the government towards domestic trial operations is further encouraging the demand for sustainable and compliant packaging. Moreover, the presence of regulatory programs such as Health Canada’s modernized clinal trial framework to ensure simplified trial approvals, further propel the demand for clinical trial packaging.
   

The Europe clinical trial packaging market is anticipated to grow with a CAGR of 9% during 2025 to 2034, attributed to the surge in the number of clinical trials for biologics, orphan drugs, and personalized therapy along with an increasing regulatory emphasis on patient safety, traceability, and sustainability.
 

• The Germany clinical trial packaging market accounted for USD 322.8 million in 2024. The country has a strong biologics research infrastructure coupled with the increasing investment from the government towards clinical R&D which drives a high volume of trials, especially in oncology and rare disease sector propels the demand for clinical trial packaging. Also, Germany has a growing number of outsourced trials through CROs and CDMOs is pushing the demand for scalable GMP-compliant packaging service, which further fuels the market growth in the country.
   
• The UK clinical trial packaging market is expected to grow at a CAGR of 9.7% during 2025 to 2034. The growth of the region is fueled by the presence of post Brexit regulatory trade, which has led to fast track trial approval coupled with increasing government initiatives for early phase research. Moreover, the rise of decentralized clinical trials (DTCs) promotes the demand for patient centric and home-use packaging such as pre-dosed kits, temperature-stable containers, and tamper-evident labelling, which supports the business growth.
   
• The clinical trial packaging market in France is projected to reach USD 484.7 million by 2034, influenced by the government backed healthcare innovation program that encourage clinical trials, especially for oncology, rare disease, and biologics. Additionally, the surge in usage of cold chain dependent biologics further propels the demand for validated temperature-controlled packaging.
   
• The Italy clinical trial packaging market accounted for USD 146.2 million in 2024. The growth of the market in Italy attribute to increasing clinical trials for export bound therapy, which rely on customizable, and specialized packaging formats such as multi dose kits, pre-filled vials, and secondary labelling. Moreover, the rapid expansion of the parenteral and biologics sector is pushing the demand for high quality, flexible and tamper proof sealing solutions, which further contributes to the market growth.
   
• The Spain clinical trial packaging market is projected to grow at a CAGR of 8.3% till 2034. The rapid expansion of clinical research sector in Spain coupled with the nation’s emphasis towards EU funded clinical trials has created a high demand for compliant, efficient, and specialized packaging solutions. Also, the rapid growth of contract research and manufacturing organizations (CROs/CDMOs) along with expanding cold chain infrastructure drives the adoption of temperature-controlled and traceable packaging solutions, which is expected to support market growth.
   

The Asia Pacific region held a share of 20.5% of the global clinical trial packaging market in 2024. The Asia Pacific region, leaded by China, Japan, India and South Korea is growing due to the rapid expansion of the clinical research industry along with the increasing pharmaceutical production and export. Moreover, the increasing government investment towards biologics, personalized medicines, and vaccine trials pushes the demand for specialized, cold chain enabled, and compliant packaging solutions, further contributing to the growth of the market.
 

• The clinical trial packaging market in China is projected to reach USD 1.1 billion by 2034. Stringent government regulations supporting the clinical research infrastructure along with the increasing demand for tamper evident, serialized, and temperature-controlled packaging, are the key growth drivers in the country. Moreover, the nation’s focus towards local and multinational clinical trials, particularly in the biologic and vaccine development further pushes the market growth.
   
• The Japan clinical trial packaging market accounted for USD 138.9 million in 2024, attributed to rapid adoption of advanced clinical research in precision medicine, which rely on high quality and specialized packaging for injectable and biologics drugs. Furthermore, the focus of Japan towards innovation in clinical trial methods coupled with the presence of leading CROs and CDMOs is fuelling the growth of market in the region.
   
• The India clinical trial packaging market is anticipated to grow at a CAGR of over 15% up to 2034. The rapid expansion of contract pharmaceutical manufacturing has led to increased demand for scalable, export-compliant, and tamper-evident packaging while ensuring with global compliance standards. Additionally, the ban on single-use plastics by the government has resulted in a shift toward sustainable clinical trial packaging which is pushing the demand for recyclable materials and reusable cold chain solutions.
   

The Latin America clinical trial packaging market was valued at USD 178.5 million in 2024, fueled by the expansion of pharmaceutical industry coupled with the increasing participation in global trials, which further pushes the demand for global compliant, traceable, and cold chain capable packaging. Additionally, the rise in clinical activity in Brazil, Mexico, and Argentina further drive the market growth.
 

The MEA region estimated to grow at a CAGR of 7.8% during 2025 to 2034. The clinical trial packaging market in the Middle East & Africa is driven by increasing investment by government in vaccine research, oncological trials, and infectious disease study which require affordable, durable, and regulatory compliant packaging. Furthermore, the expansion of regional pharmaceutical manufacturing and logistics industry is propelling growth for export ready and cost-effective packaging for cross border trade, which further support the growth of clinical trial packaging in the region.
 

Clinical Trial Packaging Market Share

The clinical trial packaging industry is highly competitive and fragmented with the presence of established global players as well as local players. The top 5 companies in the global market are Almac Group, Sharp Services, LLC, WestRock Company, Gerresheimer AG, and Amcor plc, collectively accounting for a share of 34% market share. Leading companies in the market are investing in compliance driven innovation such as temperature-controlled packaging, tamper-evident solution, and smart packaging to meet the strict regulations from several bodies such as FDA, EMA, and ICH. The advanced clinical trial packaging solutions are focusing on the cold chain integrity, serialization, and patient centric design to cater the growing demand for biologics, gene therapy, and decentralized clinical trials (DTCs).
 

Packaging manufacturers are rapidly adopting the eco-friendly materials for cold chain packaging and recyclable secondary packaging to align with global sustainability goals and regulatory push for green clinical operation. Digital tracking technology and smart labelling techniques such as QR codes, RFID tags, and smart labels which can improve consumer engagement and reducing operational costs around several industries. Additionally, Government’s initiative such as U.S. FDA Drug Supply Chain Security Act and Europe Union’s FMD regulations are further pushing investment towards advanced clinical trial packaging solutions, which offer serialization, tamper proof technology, and digital compliance tools to strengthen their competitive landscape.
 

Clinical Trial Packaging Market Companies

The clinical trial packaging industry features several prominent players, including:

• Adare Pharma Solutions
• Adelphi Healthcare Packaging
• Almac Group
• Amcor plc
• AptarGroup, Inc.
• Berry Global Inc. 
• Brentwood Industries, Inc. 
• Caprihans India Limited
• CCL Industries Inc.
• DWK Life Sciences
• Gerresheimer AG
• Korber AG
• Parexel International (MA) Corporation
• SCHOTT AG
• SGD Pharma
• Sharp Services, LLC
• TA Instruments
• WestRock Company
• Yourway
   

Almac Group offers integrated service spanning supply chain management such as interactive response technology (IRT) and clinical packaging through Almac One platform, which enable real time data visibility and risk mitigation. Additionally, this firm offers Just in Time manufacturing (JTM) via its Almac adapt packaging technology which reduces overage and waste while supporting cell and gene therapy.
 

Gerresheimer AG, a close competitor operating in the same vertical is known for its extensive portfolio of products and specializes in Type 1 borosilicate glass to manufacture vials and ampules, which meet highest packaging standards. This company also offers clinical trial kits with their Gx RTF vials, closure, and seals from early phase trial to commercialization.
 

Clinical Trial Packaging Market News

• In March 2024, Myonex has entered into a strategic agreement with the owner of Creapharm group to acquire their Creapharm Clinical Packaging & Distribution and Commercial Packaging business and bioservices, which are headquartered in France. This acquisition was aimed to strength the Myonex landscape in clinical packaging, labelling, and distribution sector.
   
• In October 2022, Myonex completed its acquisition of clinical trial and packaging business named Hubertus Apotheke situated in Germany. This acquisition was aimed to strengthen their resource and capability for packaging and sourcing in Europe.
   
• In September 2024, PCI Pharma Services is investing more than USD 365 million in infrastructure supporting the clinical and commercial-scale final assembly and packaging of drug-device combination products utilizing advanced drug delivery systems, with an emphasis on injectable formats.
   

The clinical trial packaging market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue (USD Million) and volume (Kilo Tons) from 2021 to 2034, for the following segments:

Click here to Buy Section of this Report

By Material Type       

• Plastic 
• Glass   
• Metal 
• Paper & paperboard  

By Product Type       

• Syringes          
• Vials & ampoules       
• Blisters
• Tubes  
• Bottles
• Bags & pouches          
• Kits and packs
• Others

By End Use     

• Research laboratories
• Clinical research organizations          
• Drug manufacturing facilities

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • Saudi Arabia
  • South Africa
  • UAE